Hello Atlas Partner Custom Blocks - Cloned

General

Drive Your Rare Disease Research

The path to rare disease drug development can be as unique as the 7,000 identified rare diseases. However, each therapeutic success story provides new technologies, approaches, and insights that can be applied across the rare disease community.

What can we accomplish together?

Where to start your rare disease drug development?

Platforms such as high-throughput screening (HTS), cell-based assays, and research models can be designed to mimic specific diseases using CRISPR and stem cell technology, providing more disease-relevant data for safety studies and translation to the clinic.

 •   Research Models
 •   Antisense Oligonucleotide Screening Services (ASO)
 •   CRISPR
 •   Stem Cells
 •   High-Throughput Screening
 •   High Content Imaging
 •   Cell-Based Assays
 •   Chemistry Services
 •   In Vivo Pharmacology Models
 •   Safety Studies

 

Screen and Profile with iPSC-Derived Human Cells

Now available through our exclusive partnership with Bit Bio, and its precise opti-ox cellular reprogramming technology, human iPSC-derived cell models become consistent, scalable, and reproducible. Generated in large quantities and varied tissue types, Bit Bio’s reprogrammed cell types are an excellent tool to support your high-throughput screening campaigns.


The structure of atoms is the basis for the artificial intelligence assessment of difficult, intractable and atypical targets such as protein protein interactions and protein ligand interactions during hit id and hit finding using services from Charles River and Atomwise AtomNet.

Artificial Intelligence For Drug Discovery

 By partnering with Charles River, clients gain access to AtomNet™, a patented AI platform developed by Atomwise for the prediction of small molecule binding to protein targets. AtomNet™ is the world’s first deep neural network for structure-based drug discovery applications.

Incorporate AI


blue and green microscopic image of neural stem cells

Human iPSC-derived Cells for CNS Drug Discovery

Using cellular reprogramming technology, scientists have manipulated induced pluripotent stem cells (iPSCs) to create a library of robust, reproducible neural cells suitable for high-throughput screening. Learn how this new technology can enhance your translational CNS research with the ability to perform phenotypic screening with disease-relevant neural cells.

Watch The Webinar


red stem cells

E28: Building a Stable of Stem Cells

Bit Bio is the latest in a chain of stem cell research that stretches back for decades. Stem cells have been an active part of the medical research discourse since the 1960s, but even today we are discovering new ways to harness their potential. Stem cells have the potential to become any cell that the body needs – they are the raw material that forms the building blocks of life. Isolating and identifying them was a breakthrough for medical research.

Listen to the Podcast

Drive Your Immunology Research

When our immune system is inappropriately activated this can result in chronic inflammation and autoimmune disease. Advances in immunology testing have clarified the role the immune system plays in many different disease areas, even those that have not been traditionally thought of as having an immune component. Charles River’s expert immunologists can support your immunology programs with a wide selection of in vivo and in vitro immunology assays, inflammation models, and autoimmune models, across numerous therapeutic areas, like vaccine development, infectious disease, and immuno-oncology.

What can we accomplish together?

In Vivo Immunology Models

 •   Atopic Dermatitis Model
 •   Bleomycin-Induced Scleroderma
 •   Carrageenan Footpad Edema Model
 •   Contact Dermatitis Models
 •   IBD Mouse Models
 •   Imiquimod-induced Psoriasis Model
 •   Nephrotoxic Antiserum Nephritis
 •   Pharmacodynamic Models
 •   Rheumatoid Arthritis Models
 •   Systemic Lupus Erythematosus
 •   Infectious Disease Models
 •   Immunology Testing

In Vitro Immunology

 •   Fibrosis Assays
 •   T Cell Assays
 •   B Cell Assays
 •   Immuno-oncology Assays


microscopic rending of t cells to show immunology services at CRL

Mitigate Risk with Early Immunology Data

Don’t forget immunology endpoints to develop the best translational path for your therapeutic, provide detailed regulatory expectations, and offer technical expertise in required assay formats. By using this comprehensive approach, you’ll have the most rapid and cost-effective program possible, from proof-of-concept through safety assessment and the clinic.

Watch Now


Validated In Vitro Immunology Assays

 •   Fibroblast Activation Assay
 •   Chemotaxis Assay: Monocytes
 •   Chemotaxis Assay: Neutrophils
 •   Conventional Dendritic Cells Activation Assay
 •   Plasmacytoid Dendritic Cells Activation Assay
 •   T Cell Transfer of Inflammatory Bowel Disease

In a truly translational approach to discovery and development, we combine our inflammation models and autoimmune models with relevant biomarkers like flow cytometry and histologic analysis, for a study design tailored to meet the goals of your immunology programs.


Immuno-oncology drug discovery continuum

Immuno-Oncology Translational Research

Every step along the immuno-oncology drug discovery continuum reveals unique insights that inform, predict, and progress immunotherapies, moving you from T cell-based target discovery and validation assays to in vivo efficacy and analysis in syngeneic, PD, and humanized in vivo mouse models, and ultimately to the clinic.

Read More


microscopic rending of t cells

Evaluating Autoimmune Disease Targeted Therapies that Reprogram the Immune System

Our experts explain how combining disease-relevant models, in vitro inflammation models, and autoimmune T cell assays creates a clear picture of how your therapy is reprogramming the immune system.

Watch Now


3D image of intestinal bacteria

The Therapeutic Axis of Microbiome, Inflammation, and Immune Response

 Using a model of inflammatory colitis, Dr. Rana Samadfam will explain how gut microbiota affects the induction, education and function of the immune system, and share how live therapeutics can affect inflammatory cytokines, dysbiosis, and the immunologic response.

Watch The Webinar

Drive Your CNS research

CNS drug discovery isn't for the faint of heart. We can't be deterred by clinical failures, but it's clear that some approaches aren't working. It's time to start over, building upon the foundations of our current research. It's time to explore new tools and techniques, gathering the data that drives confident decisions in the earliest stages of development. It's time to break through with discovery of new, long-awaited therapies. Collaboration is key, as we pool knowledge and share experience that will allow us all to reach our goals.

What can we accomplish together?

Translational Tools for Neuroscience Discovery

Phenotypic assays using various neuronal cellular and animal models are robust tools to discover new disease targets, perform high throughput screens, understand mechanism of action, and develop clinically relevant biomarkers. Our comprehensive suite of imaging and electrophysiology modalities, behavioral and other biomarker methods and endpoints enable more effective decision-making to help move your research forward.

Models, Services & Tools

 •   Neuroscience Drug Discovery Overview
 •   Portfolio of Validated Neurological Disease Animal Models
 •   Preclinical Imaging Capabilities for Neurological Diseases
 •   Translational Tools for Neuroscience Drug Discovery
 •   Neuroscience Capabilities From Rodents to Large Animal

 

Ion Channel Screening Services

 •   Ion Channel Selectivity Profiling: Neurodegeneration/Stroke
 •   Ion Channel Selectivity Profiling: Pain/Inflammation
 •   Ion Channel Selectivity Profiling:Psychiatric Disorder
 •   Ion Channel Selectivity Profiling: Seizure/Convulsion


Colorful illustration of microglia cells which are the primary immune cell of the brain, depicted to showcase the concept of neuroinflammation.

Why Study Neuroinflammation?

How does the gut microbiome contribute to neuroinflammation? Watch the videos below to learn how to build your neuroscience research portfolio by going outside the neuron and into the immune system.

Binge Watch The Symposium


Disease Areas

Neurodegeneration

 •   Alzheimer’s Disease
 •   Parkinson’s Disease

Pain

Neuroinflammation

 •   Multiple Sclerosis
 •   LPS-Induced Cytokine Release Model

Rare Disease

 •   Amyotrophic Lateral Sclerosis
 •   Huntington’s Disease
 •   Batten’s Disease
 •   Duchenne Muscular Dystrophy

Psychiatric Disease

Brain Injury


blue and green microscopic image of neural stem cells

Neuroscience Webinar Collection

Learn more about our neuroscience portfolio by watching our CNS webinar series.

Browse CNS Webinars


The structure of atoms is the basis for the artificial intelligence assessment of difficult, intractable and atypical targets such as protein protein interactions and protein ligand interactions during hit id and hit finding using services from Charles River and Atomwise AtomNet.

Artificial Intelligence For Drug Discovery

 By partnering with Charles River, clients gain access to AtomNet™, a patented AI platform developed by Atomwise for the prediction of small molecule binding to protein targets. AtomNet™ is the world’s first deep neural network for structure-based drug discovery applications.

Incorporate AI


The CNS Virtual Tour

High attrition rates are common when developing a neurological drug. Challenges from crossing the blood-brain-barrier to choosing the right model can pose costly risks. Learn how our team can help guide you from the earliest stages in chemistry to ADME/ DMPK to high-throughput screening to complex in vitro biology models & assays.

Tour Our CNS Facilities

 

Drive Your Oncology Research

Charles River’s experience with oncology drug discovery spans all phases, from target identification to IND studies. Utilizing the most effective combination of tools available to identify promising compounds, we work with our partners to design studies by selecting from amongst a broad range of well-characterized tumor models. Charles River is driving oncology drug discovery across a range of modalities including small molecules, immune therapies, biologics, and cell therapies.

What can we accomplish together?

In Vivo Cancer Models:

Combining these cancer models with appropriate translational tools like ELISpot, flow cytometry, imaging, gene expression analysis, and tumor microdialysis, you can develop the most efficient, relevant study design and screening method to identify promising compounds and optimize lead candidates.

 •   Cell line-derived xenograft models in mice and rats
 •   Patient-derived xenograft (PDX) models
 •   Syngeneic models
 •   Humanized mice tumor models
 •   Orthotopic models
 •   Single mouse trials
 •   Cachexia models
 •   Graft versus Host models
 •   Immuno-oncology pharmacodynamic models


Image of tumor microenvironment

Microdialysis: A Novel Tool to Sample the Tumor Microenvironment

Learn how microdialysis, a uniquely sensitive method for sampling and quantifying multiple immunomodulators and oncometabolites, elucidates the mechanisms by which oncology therapies modulate the TME. Watch The Webinar


Oncology Assays:

Our range of cancer cell-based assays include patient-derived xenograft (PDX) assays and assays representing the entire tumor microenvironment (TME), so that your therapies are not only tested for their effect on real patient materials but also their interaction with human immune systems.

 •   In vitro PDX assays
 •   3D tumor assays
 •   Immune-mediated tumor killing assays
 •   Immuno-oncology tumor cell based assays
 •   Immuno-oncology T cell based assays
 •   Immuno-oncology natural killer cell based assays
 •   Immuno-oncology macrophage assays
 •   Immuno-oncology dendritic cell assays
 •   Immuno-oncology neutrophil assays
 •   Fibroblast assays

 

Partnership Technologies:

 •  Kibur Medicial Technology:  A cost effective way to administer and measure the effects of drugs injected directly into tumors. When used in animal models in the preclinical setting, this translational technology drives decisions with data that answers challenging questions about your drug’s performance – alone or in comparison/combination with other therapies – within the tumor microenvironment.
 •   Cypre Partnership:  3D tumor models to predict therapeutic efficacy in an accurate model of the tumor microenvironment; high content analysis screening option for cancer immunotherapy and targeted therapy. 


The Impact of the Tumor Microenvironment | Rhiannon Jenkinson, Director of Science at Charles River

In this video, Rhiannon Jenkinson discusses the impact of the Tumor Microenvironment on immune-oncology drug development, and how the immune system can be harnessed to fight cancer.


In Vitro Cytotoxicity Testing of CAR-T Cells | Sanne Demandt, Group Leader for Biology at Charles River

In this video, Sanne Demandt discusses in vitro cytotoxicity testing of CAR T cells.


The structure of atoms is the basis for the artificial intelligence assessment of difficult, intractable and atypical targets such as protein protein interactions and protein ligand interactions during hit id and hit finding using services from Charles River and Atomwise AtomNet.

Artificial Intelligence For Drug Discovery

 By partnering with Charles River, clients gain access to AtomNet™, a patented AI platform developed by Atomwise for the prediction of small molecule binding to protein targets. AtomNet™ is the world’s first deep neural network for structure-based drug discovery applications.

Incorporate AI

Your Partner for Cell and Gene Therapy Research and Development

For more than 70 years, Charles River has been on the leading edge of supporting the development of novel therapeutics and we are proud of our extensive and growing contribution in supporting cell and gene therapy research and development.

With our end-to-end comprehensive portfolio, Charles River has the cell and gene therapy services and products, along with scientific and regulatory experts to fully support your integrated program from start to finish.

Conducted over 900 cell & gene therapy studies in 2020
Supported the development of FDA-approved cell & gene therapies
100 plus years of combined scientific experience

 

Browse our cell and gene therapy services and products

Working as an extension of your own team, our scientists and technicians share your goal of delivering safe, effective products to waiting patients. Explore how we can help with comprehensive cell and gene therapy services, every step of the way.

 

Cell Sourcing and Engineering

 •   Highly characterized, reliable donor pool for allogeneic cell therapy development, robust apheresis collection network, RUO, clinical grade, GMP-complaint cellular materials via HemaCare and Cellero
 •   Isolated immune cells and custom antigen-specific T cells
 •   Engineered antibodies for cell therapy discovery
 •   Target engineering and model development with CRISPR and RNAi technology and expertise

 

Exploratory to Candidate Delivery

 •   In vivo stem cell engraftment and biodistribution studies
 •   In vivo pharmacology models and assays
 •   In vivo imaging, nuclear imaging (PET, SPECT), MRI-guided gene delivery
 •   Research models supporting human cell engraftment/transfer
 •   Engineered antibody libraries for in vitro and in vivo CAR-T Testing
 •   Stem cell platforms
 •   Gene editing and screening ASOs, CRISPR/Cas9, RNAiBioinformatics services

 

Nonclinical Research to IND-enabling for Cell and Gene Therapy Development

 •   Non-clinical research to IND and laboratory support
 •   In vivo and analytical support
 •   Surgery, specialized administration and dosing routes
 •   DART
 •   Specialty models and endpoints
 •   Pathology
 •   Single combination non-GLP and GLP pharmacology and toxicology studies
 •   Method development, validation, and sample analysis (early screening through nonclinical)
 •   Clinical support


image of cells

New Manufacturing Capabilities to Bring Your Products Across the Finish Line

With our acquisition of Cognate BioServices and Cobra Biologics we have added premier development and manufacturing capabilities to our comprehensive portfolio of cell and gene therapy services.
Learn more


Charles River offers end-to-end development services for cell and gene therapy research. The Charles River cell and gene therapy research scientists present various presentations sharing insights on our services offered.

Cell and Gene Therapy Development Educational Resource Series

In these educational videos, our experts describe critical considerations, key strategies, and the technologies that can make your program a success.
Watch Now


Scientists looking through a microscope.

Tailored Preclinical Support for Your Cell & Gene Therapies

The complexity of cell and gene therapies, combined with limited regulatory precedent, makes these treatments especially challenging to develop. With the right partner, however, there’s no need to reinvent the wheel. See how we can help you design and execute a robust, efficient program that delivers accurate data to authorities.
Watch the Videos

Still have questions?

Ask an Expert

Cardiovascular and Metabolic Study Models

Our scientists can help biopharmaceutical companies engaged in cardiovascular and metabolic disease drug discovery research advance their program. We provide a number of in vivo pharmacology models for metabolic and cardiovascular diseases including...

 •   Nonalcoholic Steatohepatitis (NASH)
     •   OB/OB Mouse Model
     •   CDAA Mouse Model
 •   Type 1 Diabetes
 •   Type 2 Diabetes
 •   Fatty Liver Disease
 •   Dyslipidemia and Atherosclerosis
 •   Vascular Inflammation

Combining our well-characterized in vivo models and broad suite of translational biomarkers, our partners the flexibility they need to demonstrate the therapeutic efficacy of their compounds.


This diet-induced mouse model is a common NASH Model used in our drug discovery studies.

Learn More About Our NASH Models

Charles River maintains a colony of pre-conditioned mice with diet-induced, biopsy-confirmed nonalcoholic steatohepatitis (NASH) for rapid study starts.

Download the Data


The structure of atoms is the basis for the artificial intelligence assessment of difficult, intractable and atypical targets such as protein protein interactions and protein ligand interactions during hit id and hit finding using services from Charles River and Atomwise AtomNet.

Artificial Intelligence For Drug Discovery

 By partnering with Charles River, clients gain access to AtomNet™, a patented AI platform developed by Atomwise for the prediction of small molecule binding to protein targets. AtomNet™ is the world’s first deep neural network for structure-based drug discovery applications.

Incorporate AI


Assess Clinically Relevant End Points

Successful drug discovery relies on the selection of drug candidates with good in vivo pharmacokinetic properties, appropriate preclinical safety profiles and data packages supporting on-target effects that can be assessed in multiple animal models. Our Discovery Services group is made up of skilled technicians and scientists with decades of experience in big pharma and biotech who collectively have seen hundreds of programs move through the discovery process. We can guide your research towards a wide array of potential analytical endpoints, including:

 •   LC-MS
 •   ELISA
 •   Immunoassays
 •   Chemistry and immunohistochemistry
 •   PCR
 •   Cell and enzyme-based assays and screening
 •   q-NMR whole-body composition
 •   Rodent activity and whole-body calorimetry
 •   Custom in vivo, in vitro and ex vivo readouts

Simply put, we offer a suite of services to get you a go/no-go answer on your Cardiovascular and Metabolic drug discovery programs.

What can we accomplish together?

Ophthalmic Diseases Services

Charles River offers validated disease models that can be used for non-GLP screening studies and more definitive proof-of-concept studies for which we can advise on study designs. We have an extremely low incidence (<0.001%) of adverse complications due to intraocular dosing procedures. Board-certified veterinary ophthalmologists are readily accessible, and we maintain strong industry ties to leading experts in ophthalmology, neurophysiology and surgery.

What can we accomplish together?

Ocular In Vivo Services

 •   Choroidal Neovascularization Model
 •   Corneal Neovascularization Model
 •   LPS-Induced Uveitis Model
 •   Retinal Degeneration & Neuroprotection Model
 •   Normotensive & Hypertensive Intraocular Pressure Models<
 •   Ocular Analysis Methods


The structure of atoms is the basis for the artificial intelligence assessment of difficult, intractable and atypical targets such as protein protein interactions and protein ligand interactions during hit id and hit finding using services from Charles River and Atomwise AtomNet.

Artificial Intelligence For Drug Discovery

 By partnering with Charles River, clients gain access to AtomNet™, a patented AI platform developed by Atomwise for the prediction of small molecule binding to protein targets. AtomNet™ is the world’s first deep neural network for structure-based drug discovery applications.

Incorporate AI


Picture of an eye to represent the ocular in vivo pharmacology studies offered at Charles River Labs to support your drug discovery.

Supporting the Discovery & Development Of Ocular Drug Products

With an integrated approach to ophthalmology research, Charles River has critical understanding of ocular diseases and the technical ability to guide our clients through the development process as efficiently as possible.

Learn More


Routes of Administration for Ocular Medications

 •   Topical instillation
 •   Intravitreal/subretinal injections
 •   Subconjunctival/subtenon injections
 •   Intracameral injections
 •   Internal/external implants
 •   Transplants (corneal)

In addition, we offer supplementary services for your ocular program, including optical coherence tomography (OCT), electroretinography (ERG), tonometry (IOP), digital fundus photography, pachymetry (corneal thickness measurement), vitrectomy, quantitative autoradiography, drug metabolism and enhanced microscopic evaluation.